Halozyme Therapeutics Inc (HALO)
49.00
+3.30
(+7.22%)
USD |
NASDAQ |
Nov 22, 16:00
48.52
-0.48
(-0.98%)
Pre-Market: 20:00
Halozyme Therapeutics Cash from Operations (Quarterly): 115.38M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 115.38M |
| June 30, 2024 | 55.79M |
| March 31, 2024 | 129.43M |
| December 31, 2023 | 102.35M |
| September 30, 2023 | 132.41M |
| June 30, 2023 | 66.84M |
| March 31, 2023 | 86.96M |
| December 31, 2022 | 82.45M |
| September 30, 2022 | 69.64M |
| June 30, 2022 | 40.22M |
| March 31, 2022 | 47.80M |
| December 31, 2021 | 82.52M |
| September 30, 2021 | 121.74M |
| June 30, 2021 | 36.89M |
| March 31, 2021 | 58.30M |
| December 31, 2020 | 50.92M |
| September 30, 2020 | 6.084M |
| June 30, 2020 | 3.294M |
| March 31, 2020 | -4.844M |
| December 31, 2019 | -26.62M |
| September 30, 2019 | -29.59M |
| June 30, 2019 | -24.79M |
| March 31, 2019 | -4.424M |
| December 31, 2018 | 10.46M |
| September 30, 2018 | -18.93M |
| Date | Value |
|---|---|
| June 30, 2018 | -18.86M |
| March 31, 2018 | -22.18M |
| December 31, 2017 | 153.25M |
| September 30, 2017 | 20.26M |
| June 30, 2017 | -17.00M |
| March 31, 2017 | -22.46M |
| December 31, 2016 | -15.77M |
| September 30, 2016 | -8.748M |
| June 30, 2016 | -12.84M |
| March 31, 2016 | -13.02M |
| December 31, 2015 | -15.20M |
| September 30, 2015 | -16.98M |
| June 30, 2015 | 8.938M |
| March 31, 2015 | -13.84M |
| December 31, 2014 | -0.939M |
| September 30, 2014 | -13.18M |
| June 30, 2014 | -15.77M |
| March 31, 2014 | -17.63M |
| December 31, 2013 | -15.22M |
| September 30, 2013 | -12.41M |
| June 30, 2013 | -10.96M |
| March 31, 2013 | -10.75M |
| December 31, 2012 | -16.87M |
| September 30, 2012 | -14.30M |
| June 30, 2012 | -13.76M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-26.62M
Minimum
Dec 2019
132.41M
Maximum
Sep 2023
62.88M
Average
62.57M
Median
Cash from Operations (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | -53.62M |
| Novavax Inc | -144.81M |
| Kura Oncology Inc | -43.44M |
| TransMedics Group Inc | 6.857M |
| Pulmonx Corp | -7.242M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -167.48M |
| Cash from Financing (Quarterly) | 18.56M |
| Free Cash Flow | 392.71M |
| Free Cash Flow Per Share (Quarterly) | 0.8749 |
| Free Cash Flow to Equity (Quarterly) | 112.22M |
| Free Cash Flow to Firm (Quarterly) | 117.61M |
| Free Cash Flow Yield | 6.17% |